Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates

• Published in: The Prostate 1999-09, Vol.40 (4), p.248-255
• Main Authors: Gann, Peter H., Klein, Karin G., Chatterton, Robert T., Ellman, Allison E., Grayhack, John T., Nadler, Robert B., Lee, Chung
• Format: Article
• Language: English
• Subjects: Aged; Biological and medical sciences; Disease Progression; EGF; Epidermal Growth Factor - analysis; Growth Substances - analysis; Humans; Male; Medical sciences; Nephrology. Urinary tract diseases; prostate; Prostate - chemistry; prostatic fluid; Prostatic Hyperplasia - metabolism; Prostatic Neoplasms - chemistry; Radioimmunoassay; TGF-α; TGF-β; Transforming Growth Factor alpha - analysis; Transforming Growth Factor beta - analysis; Tumors of the urinary system; Urinary tract. Prostate gland
• ISSN: 0270-4137; 1097-0045
• DOI: 10.1002/(SICI)1097-0045(19990901)40:4<248::AID-PROS6>3.0.CO;2-M

BACKGROUND Although growth factors such as epidermal growth factor (EGF), transforming growth factor (TGF)‐α, and TGF‐β are important regulators of prostate cell growth in vitro and in animal models, evidence to support their role in human prostate cancer development remains sparse. We previously showed that men without prostate cancer have concentrations of EGF and TGF‐α in expressed prostatic fluid (EPF) that are individually distinct and stable over time. This study addressed whether growth factor levels in EPF are associated with the presence or progression of prostate cancer. METHODS We measured levels of immunoreactive EGF, TGF‐α, and TGF‐β1 in stored EPF samples from three age‐matched groups: 19 men with untreated, histologically diagnosed prostate cancer (CaP), 38 with benign prostate hyperplasia (BPH), and 19 with normal prostate glands (NPD). RESULTS Median TGF‐α was lower in the BPH group (0.45 ng/ml) than in either CaP (0.63 ng/ml) or NPD (0.58 ng/ml) groups (P = 0.03 and 0.12, respectively). For EGF, the median was lowest in the CaP group and highest in the NPD group (92.5 ng/ml vs. 175.5 ng/ml, P = 0.006). For TGF‐β1, the median level in CaP was 2.7 times higher than the median level among all controls (6.65 ng/ml vs. 2.46 ng/ml, P = 0.002). Growth factor levels were not associated with tumor stage or Gleason score. However, the single case with distant metastases had TGF‐β1 levels 23‐fold higher than the CaP median. CONCLUSIONS The results suggest that at the time of CaP diagnosis, EGF levels in EPF are significantly lower, and TGF‐β1 levels significantly higher, than normal. Marked overexpression of TGF‐β1 in advanced CaP might be reflected in extremely high EPF levels. Prostate 40:248–255, 1999. © 1999 Wiley‐Liss, Inc.